Feinstein Institutes announces partnerships for Covid-19 trials

23rd March 2020 (Last Updated September 7th, 2020 07:12)

The Feinstein Institutes for Medical Research at Northwell Health in the US has partnered with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to study potential treatments for Covid-19.

Feinstein Institutes announces partnerships for Covid-19 trials
Feinstein Institutes president and CEO Kevin Tracey, discusses the three Covid-19 clinical trials during a virtual press conference. Credit: Northwell Health.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

The Feinstein Institutes for Medical Research at Northwell Health in the US has partnered with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to study potential treatments for Covid-19.

Feinstein Institutes is currently conducting three clinical trials of patients infected with moderate to severe Covid-19 infection who were admitted to Northwell Health hospitals.

The aim is to determine effective treatments that could improve recovery and expedite hospital discharge.

Northwell Health president and CEO Michael Dowling said: “We’ve joined with three outstanding companies to immediately begin clinical trials for patients now suffering from Covid-19 and are determined to do all we can to stop the virus in its tracks.”

Alliance with Gilead

Feinstein Institutes will assess the safety and efficacy of Gilead’s remdesivir in decreasing the intensity and duration of the novel coronavirus infection in hospitalised patients in two clinical trials.

The first randomised global trial will recruit up to 400 patients with severe Covid-19 and will evaluate two dosing durations of the drug given intravenously.

Conducted in alliance with Gilead, the second trial will compare two different durations of remdesivir to current standard of care in up to 600 patients with moderate disease globally.

Gilead already launched Phase III clinical trials of the drug to treat Covid-19 in adults.

Partnership with Regeneron and Sanofi

Feinstein Institutes has partnered with Regeneron and Sanofi to perform an adaptive, randomised trial of sarilumab in around 400 severe or critical hospitalised patients at various US sites.

The trial is designed to investigate the safety and efficacy of the anti-interleukin-6 antibody.

IL-6’s role in Covid-19-related pneumonia is supported by preliminary findings from a Chinese trial. China recently approved the use of an IL-6 inhibitor for severe or critical Covid-19 treatment.

Earlier this month, Sanofi and Regeneron launched a clinical programme of rheumatoid arthritis drug sarilumab (Kevzara) to treat hospitalised, severe Covid-19 patients.